Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine

Journal of Hypertension

Volumn 21, Issue 5, 2003, Pages 1003-1010

  Lund Johansen, Per ^a   Stranden, Einar ^b   Helberg, Steiner ^c   Wessel Aas, Terje ^h   Risberg, Knut ^d   Roønnevik, Per K ^e   Istad, Helge ^f   Madsbu, Sverre ^g  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b AKER UNIVERSITY HOSPITAL   (Norway)

^c Department of Plastic and ENT Surgery   (Norway)

^d Skedsmo Medical Center   (Norway)

^e Fana Heart Center   (Norway)

^f Theresesgate Medical Center   (Norway)

^g Elverum Medical Center   (Norway)

^h NONE

Author keywords

Amlodipine; Essential hypertension; Lercanidipine; Oedema; Post menopausal

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; LERCANIDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DYSPNEA; FLUSHING; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; LEG EDEMA; LEG SWELLING; MAJOR CLINICAL STUDY; PHYSICAL EXAMINATION; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN ALLERGY; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TITRIMETRY; TREATMENT OUTCOME; VOLUMETRY;

EID: 0037637556     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200305000-00026     Document Type: Article

References (30)

1. Subcommittee G. World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151-183.
2. Blood Pressure Lowering Treatment Trialist Collaboration. Effect of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet 2000; 355:1955-1964.
3. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet 2001; 358:1305-1315.
4. Messerli FH. Vasodilatatory oedema: a common side effect of antihypertensive therapy. Am J Hypertens 2001; 14:978-979.
5. Lund-Johansen P. Hemodynamic effects of calcium antagonists in hypertension. In: Epstein M (editor): Calcium antagonists in clinical medicine (3rd edn). Philadelphia, Pennsylvania: Hanley & Belfus; 2002, pp. 315-335.
6. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356:366-372.
7. Haria M, Wagstaff A.J. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs 1995; 50:560-586.
8. Papavassiliou MV Vyssoulis GP, Karpanou EA, Nelegrinos DA, Giannakopoulou AE, Toutouzas PK. Side effects of antihypertensive treatment with calcium channel antagonists (abstract). Am J Hypertens 2001; 14:114A.
9. Herbette LG, Vecchiarelli M, Leonardi A. Lercanidipine: short plasma half-life, long duration of action. J Cardiovasc Pharm 1997; 29(suppl 1):S19-S24.
10. Leonardi A, Poggesi E, Taddei C, Guarneri L, Angelico P, Accomazzo MR, et al. In vitro calcium antagonist activity of Lercanidipine and its enantiomers. J Cardiovasc Pharm 1997; 29(suppl 1):S10-S18.
11. Guarneri L, Sironi G, Angelico P, Ibba M, Greto L, Colombo A, et al. In vitro and in vivo vascular selectivity of Lercanidipine and its enantiomers. J Cardiovasc Pharm 1997; 29(suppl 1):S25-S32.
12. Ambrosioni E, Circo A. Activity of Lercanidipine administered in single and repeated doses once daily as monitored over 24 h in patients with mild to moderate essential hypertension. J Cardiovasc Pharm 1997; 29(suppl 1):S16-S20.
13. Omboni S, Zanchetti A. Antihypertensive efficacy of Lercanidipine at 2.5, 5 and 10 mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements. J Hypertens 1998; 16:1831-1838.
14. Giorgio LA De, Orlandini F, Malasoma P, Zappa A. Double-blind, cross-over study of Lercanidipine versus Amlodipine in the treatment of mild-to-moderate essential hypertension. Curr Ther Res 1999; 60:511-520.
15. McClellan KJ, Jarvis B. Lercanidipine. A review of its use in hypertension. Drugs 2000; 60:1123-1140.
16. Versari D, Virdis A, Ghiadoni L, Magagna A, Taddei S, Salvetti A. Lercanidipine restores nitric oxide availability in the forearm of essential hypertensive patients. J Hypertension 2002; 20(suppl 4):S270.
17. Venkata R. Usefulness of Lercanidipine, a new calcium antagonist for systemic hypertension. Am J Cardiol 2002; 89:214-215.
18. Hollenberg NK. Observations on the safety of Lercanidipine, a novel CCB: adverse event data from placebo-controlled trials (poster). Annual Meeting, American Society of Hypertension; 15-18 May 2002; New York.
19. Nilsson S, Haugen GB. Volumetry in the evaluation of swelling in the ankle and foot. J Oslo City Hosp 1981; 31:11-15.
20. Stranden E. A comparison between surface measurements and water displacement volumetry for the quantification of leg oedema. J Oslo City Hosp 1981; 31:153-155.
21. Khiabani HZ, Anvar MD, Stranden E, Slagsvold CE, Kroese AJ. Ooedema in the lower limb of patients with chronic critical limb ischaemia (CLI). Eur J Vasc Endovasc Surg 1999; 17:419-423.
22. Stranden E, Kroese AJ. Venodynamics in healthy subjects and in patients with venous dysfunction. Scope Phlebol Lymphology 1998; 5:4-12.
23. Fogari R, Malamani GD, Zoppi A, Preti P, Vanesia A, Fogari E, et al. Comparative effect of Lercanidipine and nifedipine gastrointestinal therapeutic system on ankle volume and subcutaneous interstitial pressure in hypertensive patients: a double-blind, randomized, parallel-group study. Curr Ther Res 2000; 61:850-862.
24. Leonetti G, Magnani B, Pessina AC, Rappelli A, Trimarco B. Zanchetti A, on behalf of the COHORT Study Group. Tolerability of long-term treatment with Lercanidipine versus Amlodipine and lacidipine in elderly hypertensives. Am J Hypertens 2002; 15:932-940.
25. Messerli FH. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am J Hypertens 2002; 15:94S-97S.
26. Hamersvelt HW van, Kloke HJ, Jong DJ de, Koene RA, Huysmans FT. Oedema formation with the vasodilators nifedipine and diazoxide: direct local effect or sodium retention? J Hypertens 1996; 14:1041-1045.
27. Salmasi AM, Belcaro G, Nicolaides AN. Impaired venoarteriolar reflex as a possible cause for nifedipine-induced ankle ooedema. Int J Cardiol 1991; 30:303-307.
28. Grassi G, Seravalle G, Tutti C, Bertinieri G, Stella ML, Mancia G. Different behaviour of the sympathetic responses to acute and chronic blood pressure reductions induced by antihypertensive drugs. Eur Heart J 2001; 22:109.
29. Fogari R, Corradi L, Mugellini A, Preti P, Derosa G, Rinaldi A. Effects of different dihydropyridine calcium antagonists on plasma noerepinephrine in essential hypertension (abstract). Am J Hypertens 2002; 15:P-8.
30. Sabbatini M, Leonardi A, Testa R, Vitaioli L, Amenta F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000; 35:775-779.